INDP [NASD]
Indaptus Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.52 Insider Own34.10% Shs Outstand8.91M Perf Week-4.80%
Market Cap21.21M Forward P/E- EPS next Y-2.25 Insider Trans-0.65% Shs Float5.44M Perf Month-22.98%
Income-7.70M PEG- EPS next Q-0.46 Inst Own21.00% Short Float0.50% Perf Quarter-45.66%
Sales- P/S- EPS this Y88.50% Inst Trans-6.22% Short Ratio0.06 Perf Half Y-58.17%
Book/sh4.68 P/B0.51 EPS next Y12.60% ROA- Target Price13.00 Perf Year-84.05%
Cash/sh3.73 P/C0.64 EPS next 5Y- ROE- 52W Range2.13 - 28.83 Perf YTD-58.25%
Dividend- P/FCF- EPS past 5Y54.20% ROI- 52W High-91.74% Beta1.23
Dividend %- Quick Ratio10.00 Sales past 5Y- Gross Margin- 52W Low11.74% ATR0.30
Employees70 Current Ratio10.00 Sales Q/Q- Oper. Margin- RSI (14)37.96 Volatility13.14% 11.60%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.17 Prev Close2.34
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume478.57K Price2.38
Recom2.00 SMA20-12.68% SMA50-27.86% SMA200-58.82% Volume80,375 Change1.71%
May-23-22 08:00AM  
May-19-22 07:00AM  
May-18-22 04:15PM  
May-12-22 08:00AM  
May-03-22 12:20PM  
Apr-20-22 07:00AM  
Mar-23-22 07:00AM  
Mar-21-22 07:00AM  
Mar-17-22 07:00AM  
Mar-07-22 07:00AM  
Jan-14-22 09:38AM  
Jan-05-22 07:00AM  
Jan-03-22 07:00AM  
Dec-01-21 08:00AM  
Nov-15-21 07:00AM  
Nov-04-21 10:51AM  
Sep-15-21 07:00AM  
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Newman Michael JamesCSO and DirectorFeb 01Sale5.0014,13070,6921,368,356Feb 02 05:08 PM
Newman Michael JamesCSO and DirectorJan 31Sale5.005,87029,3511,382,486Feb 02 05:08 PM
Meckler Jeffrey ACEO and DirectorNov 18Buy5.8211,18765,10825,647Nov 19 09:16 AM